Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ASP5354 for intraoperative ureter visualization during abdominopelvic surgery
2025-000122-33Phase 3
- Sponsor
- Astellas Pharma
- Start
- Apr 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pudexacianinium chloride, sponsored by Astellas Pharma. Primary endpoint: Intra-participant difference in ureter conspicuity for white light versus near-infrared fluorescence.
02
Drugs
pudexacianinium chloride
Beyond the preview
Go deeper on 2025-000122-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000122-33.